Arketamine

DB19150InvestigationalSmall molecule

Arketamine is under investigation in clinical trial NCT05414422 (A Randomized, Placebo-controlled, Double-blind Study to Assess Safety and Efficacy of PCN-101 in TRD).

Mechanism: Pharmacologically active on NMDA receptor
Curator reviewed
Formula / weight: C₁₃H₁₆ClNO · 237.73 g/mol (avg)
Also known as: (+)-ketamine · (r)-(+)-ketamine · (r)-ketamine · Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2r)- · Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+)-
Code names: HR-071603 · J238.629A · PCN-101

Resolves to

Compound

UNIIY2RI13H7VWCAS33643-49-1ChEMBLCHEMBL467505ChEBI580604

Structure

InChIKeyYQEZLKZALYSWHR-CYBMUJFWSA-NSMILESCN[C@]1(CCCCC1=O)C1=CC=CC=C1Cl

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which companies are running trials of Arketamine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account